- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05066295
Validation and Reliability of the Parents Assessment of Protective Factors Survey
Strengthening Families to Prevent Child Neglect and Abuse With Community Based Protective Approaches: Culturally Appropriate Program Development and Educational Design
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The American Center for Social Policy Studies (CSSP) Center for Quality Improvement in Early Childhood (QIC_EC) defined protective factors that will form the basis of programs designed to prevent neglect and abuse, with community-based approaches. Community-based programs for primary prevention should be developed to prevent neglect and abuse, before it occurs. Existing studies in our country show that there is rarely a focus on preventing adverse childhood experiences with primary preventive approaches. Most of the studies are school-based, and aimed at increasing awareness of children and families about abuse.
This study aimed to evaluate the Turkish translation of the PAPF survey for validity and reliability and to adapt a culturally appropriate program and educational design for strengthening families, with a multidisciplinary team.
In the first step of the study, Turkish validity and reliability of the Parents Assessment of Protective Factors (PAPF) survey, will be conducted and applied to parents to determinate the protective factors. Turkish version of Adverse Childhood Experience Questionnaire (ACE), will be applied simultaneously with the PAPF survey, to identify adverse childhood experiences of parents that might affect parental resilience, parenting characteristics, and family dynamics.
In the second phase of the study, community-based family education programs that are currently being implemented in different countries will be reviewed by a multidisciplinary team (healthcare professionals, social workers and non-governmental organizations). A culturally appropriate educational primary prevention program for child neglect and abuse will be developed.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Istanbul, Tyrkia
- Marmara University School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Parents of children aged between 0 to 8 years
- Ability to read and complete the self-assessment questionnaires
Exclusion Criteria:
- Parents who do not give consent to participate in the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Turkish Validation of The Parents Assessment of Protective Factors (PAPF) Survey
Tidsramme: Baseline
|
Parents Assessment of Protective Factors (PAPF) Survey will be validated
|
Baseline
|
Turkish Reliability of The Parents Assessment of Protective Factors (PAPF) Survey
Tidsramme: Baseline
|
Parents Assessment of Protective Factors (PAPF) Survey will be tested for reliability
|
Baseline
|
Turkish Reliability of The Parents Assessment of Protective Factors (PAPF) Survey
Tidsramme: at 6 months
|
Parents Assessment of Protective Factors (PAPF) Survey will be tested for reliability
|
at 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Subscale scores for each protective factors
Tidsramme: Baseline
|
Parents Assessment of Protective Factors (PAPF) Survey subscale scores will be computed.
Higher scores indicate greater protective factors.
|
Baseline
|
Protective Factors Index (PFI)
Tidsramme: Baseline
|
Parents Assessment of Protective Factors (PAPF) Survey total scores will be summed
|
Baseline
|
Adverse Childhood Events
Tidsramme: Baseline
|
Adverse Childhood Events will be measured with Adverse Childhood Events Questionnaire. Higher scores indicate increased exposure to trauma, which have been associated with a greater risk of negative consequences. |
Baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 09.2021.848
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Familie
-
Simon Fraser UniversityUniversity of British Columbia; McMaster University; University of Victoria; Public Health Agency of Canada (PHAC) og andre samarbeidspartnereFullført
-
Institut CurieUNICANCERFullførtEwing Sarcoma Family of TumorsFrankrike
-
Istituto Ortopedico RizzoliRegione Emilia-RomagnaFullførtEwing Sarcoma Family of TumorsStorbritannia, Italia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvsluttetTilbakevendende glioblastom | IDH Family Wildtype | Tilbakevendende anaplastisk astrocytomForente stater
-
University of MinnesotaFullførtKrigsrelatert traume | Traumer mellom generasjoner | Family Mindfulness-basert intervensjon i krigsrammede familierForente stater
-
Eva Morava-KoziczHar ikke rekruttert ennåSLC35A2-CDG - Solute Carrier Family 35 medlem A2 medfødt glykosyleringsforstyrrelseForente stater
-
Hospital Ruber InternacionalRekrutteringRefraktær epilepsi | SLC35A2-CDG - Solute Carrier Family 35 medlem A2 medfødt glykosyleringsforstyrrelseSpania
-
Institut CurieRekrutteringLeukemi | Osteosarkom | Nevroblastom | Rhabdomyosarkom | Svulst i sentralnervesystemet | Ewing Sarcoma Family of TumorsFrankrike